Skip to content
value.today
Anavex Life Sciences Corp. logo

Anavex Life Sciences Corp.

AVXL
$123 Mmarket cap on Oct 26, 2026-77.0% since Jan 2024
Compare
World rank
#17,983
Revenue
—
For year ending September-2025
Net income
$-46 M
SEC filing
Employees
25
As on 2021
value.today research

Anavex Life Sciences Corp. in brief

Anavex Life Sciences Corp. is a listed company in the Biotechnology industry, based in New York, New York, USA. Its market value was $123 M on 26 October 2026, which makes it the 17,983rd largest listed company in the world and the 3,410th largest in the USA on this site. It employs about 25 people and Terrie Kellmeyer is its chief executive. Its shares trade under the symbol AVXL (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Anavex Life Sciences Corp.

Anavex Life Sciences is a person-focused, biopharmaceutical company dedicated to therapeutic discovery and development of targeted CNS treatments. The headquarters is in USA.

Anavex Life Sciences Corp. timeline

2 events, 2005–2007
  1. 2005
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2007
  4. ✎
    Renamed Anavex Life Sciences Corp.
    Formerly Thrifty Printing Inc..

Events of Anavex Life Sciences Corp. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$319 M$638 M$957 M$1.3 B2020202120222023202420252026

World rank over time

▼ down 940 places since 2020
2020-01-01: #17080#17,08020202021-01-01: #12794#12,79420212022-01-07: #8577#8,57720222022-12-25: #10700#10,70020222023-07-30: #11174#11,17420232024-01-05: #12166#12,16620242026-03-08: #7460#7,46020262026-08-01: #14210#14,21020262026-10-14: #17661#17,66120262026-10-26: #18020#18,0202026

Rank in USA: #3,431 (Jan 2020) · #2,800 (Jan 2021) · #2,403 (Jan 2022) · #2,353 (Dec 2022) · #2,457 (Jul 2023) · #2,479 (Jan 2024) · #1,318 (Mar 2026) · #2,874 (Aug 2026) · #3,323 (Oct 2026) · #3,414 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.3×
Free cash flow yield
-2.2%
Net margin
—
Operating margin
—
Return on equity
-48.9%
Liabilities / assets
8.6%
Net debt
$-15M
Profit per employee
$-1.9 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Sep 2018: revenue —, net income $-17M—FY18Fiscal year ending Sep 2019: revenue —, net income $-26M—FY19Fiscal year ending Sep 2020: revenue —, net income $-26M—FY20Fiscal year ending Sep 2021: revenue —, net income $-38M—FY21Fiscal year ending Sep 2022: revenue —, net income $-48M—FY22Fiscal year ending Sep 2023: revenue —, net income $-48M—FY23Fiscal year ending Sep 2024: revenue —, net income $-43M—FY24Fiscal year ending Sep 2025: revenue —, net income $-46M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Sep 2025——$-51M$-46M—
Sep 2024——$-53M$-43M—
Sep 2023——$-56M$-48M—
Sep 2022——$-51M$-48M—
Sep 2021——$-42M$-38M—
Sep 2020——$-31M$-26M—
Sep 2019———$-26M—
Sep 2018———$-17M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Sep 2025$-39M——$-0.54—
Sep 2024$-31M——$-0.52—
Sep 2023$-28M——$-0.60—
Sep 2022$-24M——$-0.62—
Sep 2021$-30M——$-0.54—
Sep 2020$-21M——$-0.45—
Sep 2019$-19M——$-0.54—
Sep 2018$-13M——$-0.39—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024 (from the annual report): revenue —, net income $-12M—Sep ’24Three months to Dec 2024: revenue —, net income $-12M—Dec ’24Three months to Mar 2025: revenue —, net income $-11M—Mar ’25Three months to Jun 2025: revenue —, net income $-13M—Jun ’25Three months to Sep 2025 (from the annual report): revenue —, net income $-10M—Sep ’25Three months to Dec 2025: revenue —, net income $-6M—Dec ’25Three months to Mar 2026: revenue —, net income $-5M—Mar ’26Three months to Jun 2026: revenue —, net income $8M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Anavex Life Sciences Corp. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-51 M
Net income
$-46 M

For year ending September-2025 · source: SEC filing

Balance sheet

Total assets
$104 M
Total liabilities
$9 M
Total equity
$95 M

As of September-2025

Top 100 institutional investors in Anavex Life Sciences Corp.#

As of Sep 30, 2026
165 institutions held 39.5 M shares (about 42.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 28.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Anavex Life Sciences Corp.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.8,144,147+88,519 (+1.10%)8.79%$16 MNov 13, 2026
2Vanguard Capital Management LLC4,094,908+40,319 (+0.99%)4.42%$8 MNov 13, 2026
3GMT Capital Corp2,704,364New2.92%$5 MNov 16, 2026
4Federated Hermes, Inc.2,585,094+1,513,285 (+141.19%)2.79%$5 MNov 12, 2026
5Two Sigma Investments, LP2,336,420-710,118 (-23.31%)2.52%$5 MNov 16, 2026
6Geode Capital Management, LLC2,275,241-132,232 (-5.49%)2.45%$5 MNov 6, 2026
7State Street Corp1,958,409+35,639 (+1.85%)2.11%$4 MNov 12, 2026
8Vanguard Portfolio Management LLC898,456-50,177 (-5.29%)0.97%$2 MNov 13, 2026
9Summit Financial, LLC889,069-20,361 (-2.24%)0.96%$2 MNov 12, 2026
10Goldman Sachs Group Inc889,066-1,568 (-0.18%)0.96%$2 MNov 16, 2026
11Charles Schwab Investment Management Inc886,987+152,192 (+20.71%)0.96%$2 MNov 16, 2026
12Barclays PLC868,259+114,033 (+15.12%)0.94%$2 MNov 6, 2026
13Northern Trust Corp789,290+4,796 (+0.61%)0.85%$2 MNov 16, 2026
14Marshall Wace, LLP758,238-131,285 (-14.76%)0.82%$2 MNov 13, 2026
15Vanguard Fiduciary Trust Co625,946+4,495 (+0.72%)0.68%$1 MNov 13, 2026
16Citadel Advisors LLC548,819+219,704 (+66.76%)0.59%$1 MNov 16, 2026
17Private Advisor Group, LLC432,000-72,000 (-14.29%)0.47%$1 MNov 10, 2026
18UBS Group AG430,843-189,531 (-30.55%)0.46%$1 MNov 10, 2026
19Morgan Stanley414,151+219,188 (+112.43%)0.45%$1 MNov 13, 2026
20Bank Of America Corp /de/405,033-249,262 (-38.10%)0.44%$1 MNov 16, 2026
21LPL Financial LLC357,220-48,889 (-12.04%)0.39%$1 MNov 6, 2026
22Stifel Financial Corp352,975+20,378 (+6.13%)0.38%$1 MNov 12, 2026
23Wellington Management Group LLP331,133New0.36%$1 MNov 16, 2026
24Bank of New York Mellon Corp297,437+9,238 (+3.21%)0.32%$1 MNov 5, 2026
25Nuveen, LLC226,138+43,416 (+23.76%)0.24%$0 MNov 10, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Anavex Life Sciences Corp.
#InstitutionShares heldChange (shares)% heldValueFiled
26Apella Capital, LLC223,006-4,989 (-2.19%)0.24%$0 MOct 8, 2026
27AQR Capital Management LLC214,266-748,748 (-77.75%)0.23%$0 MNov 16, 2026
28Susquehanna International Group, LLP202,280-117,249 (-36.69%)0.22%$0 MNov 16, 2026
29D. E. Shaw & Co., Inc.191,638+76,176 (+65.97%)0.21%$0 MNov 16, 2026
30Canada Pension Plan Investment Board187,300-14,500 (-7.19%)0.20%$0 MNov 16, 2026
31PVG Asset Management Corp155,207-172,137 (-52.59%)0.17%$0 MOct 19, 2026
32Los Angeles Capital Management LLC138,940+42,015 (+43.35%)0.15%$0 MNov 12, 2026
33Invesco Ltd.138,913+28,965 (+26.34%)0.15%$0 MNov 12, 2026
34Voleon Capital Management LP136,626+73,121 (+115.14%)0.15%$0 MNov 16, 2026
35Alliancebernstein L.P.135,930-10,370 (-7.09%)0.15%$0 MNov 16, 2026
36Jpmorgan Chase & Co130,130+83,363 (+178.25%)0.14%$0 MNov 12, 2026
37Alps Advisors Inc121,938+27,887 (+29.65%)0.13%$0 MNov 3, 2026
38Bridgeway Capital Management, LLC120,938-2,062 (-1.68%)0.13%$0 MNov 16, 2026
39Empowered Funds, LLC120,938New0.13%$0 MNov 13, 2026
40Rhumbline Advisers110,546-1,503 (-1.34%)0.12%$0 MNov 10, 2026
41XTX Topco Ltd94,507+61,791 (+188.87%)0.10%$0 MNov 16, 2026
42HSBC Holdings PLC93,936-8,989 (-8.73%)0.10%$0 MNov 16, 2026
43Hikari Power Ltd85,5850 (0.00%)0.09%$0 MOct 30, 2026
44Price T Rowe Associates Inc /MD/83,666+16,948 (+25.40%)0.09%$0 MNov 16, 2026
45Renaissance Technologies LLC79,999New0.09%$0 MNov 12, 2026
46Point72 Asset Management, L.P.77,502-79,984 (-50.79%)0.08%$0 MNov 16, 2026
47PNC Financial Services Group, Inc.72,401+5,779 (+8.67%)0.08%$0 MNov 6, 2026
48Deutsche Bank AG\69,291-10,041 (-12.66%)0.07%$0 MNov 6, 2026
49Cerity Partners LLC67,125-21,231 (-24.03%)0.07%$0 MNov 13, 2026
50180 Wealth Advisors, LLC63,690-7,340 (-10.33%)0.07%$0 MNov 3, 2026
51LexAurum Advisors, LLC61,135-3,915 (-6.02%)0.07%$0 MOct 19, 2026
52Cetera Investment Advisers55,845-19,276 (-25.66%)0.06%$0 MNov 13, 2026
53Ameriprise Financial Inc54,490-4,605 (-7.79%)0.06%$0 MNov 16, 2026
54Jain Global LLC51,915+29,913 (+135.96%)0.06%$0 MNov 16, 2026
55Bolton Securities Corporation50,0000 (0.00%)0.05%$0 MNov 12, 2026
56BNP Paribas Financial Markets48,088+18,772 (+64.03%)0.05%$0 MNov 12, 2026
57Hayek Kallen Investment Management47,709+600 (+1.27%)0.05%$0 MNov 13, 2026
58Wells Fargo & Company/mn46,822-69,852 (-59.87%)0.05%$0 MNov 16, 2026
59MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.44,731+2,278 (+5.37%)0.05%$0 MNov 16, 2026
60Creative Planning41,809-17,971 (-30.06%)0.05%$0 MNov 2, 2026
61Geneos Wealth Management Inc.41,800-6,300 (-13.10%)0.05%$0 MNov 9, 2026
62Bank Of Montreal /can/41,664+2,154 (+5.45%)0.04%$0 MNov 9, 2026
63Sheets Smith Wealth Management40,712-30,547 (-42.87%)0.04%$0 MOct 16, 2026
64Snowden Capital Advisors LLC40,449-35 (-0.09%)0.04%$0 MNov 16, 2026
65Foster Victor Wealth Advisors, LLC39,9250 (0.00%)0.04%$0 MOct 21, 2026
66Squarepoint Ops LLC38,861+438 (+1.14%)0.04%$0 MNov 9, 2026
67NewEdge Advisors, LLC37,919+1,029 (+2.79%)0.04%$0 MNov 13, 2026
68Opus Capital Group, LLC37,7000 (0.00%)0.04%$0 MOct 30, 2026
69Envestnet Asset Management Inc36,695-109,635 (-74.92%)0.04%$0 MNov 16, 2026
70MetLife Investment Management, LLC34,881-16,746 (-32.44%)0.04%$0 MNov 16, 2026
71Vanguard Global Advisers, LLC34,532+424 (+1.24%)0.04%$0 MNov 13, 2026
72Russell Investments Group, Ltd.31,540+8,050 (+34.27%)0.03%$0 MNov 6, 2026
73Forum Financial Management, LP30,1000 (0.00%)0.03%$0 MOct 16, 2026
74VestGen Advisors, LLC30,030New0.03%$0 MOct 27, 2026
75Osaic Holdings, Inc.29,901-4,565 (-13.24%)0.03%$0 MNov 12, 2026
76Choreo, LLC29,7090 (0.00%)0.03%$0 MOct 28, 2026
77Independent Advisor Alliance28,568-2,000 (-6.54%)0.03%$0 MNov 10, 2026
78Dimensional Fund Advisors LP27,2380 (0.00%)0.03%$0 MNov 4, 2026
79Manufacturers Life Insurance Company, The26,706+820 (+3.17%)0.03%$0 MNov 13, 2026
80Beacon Pointe Advisors, LLC23,1850 (0.00%)0.03%$0 MNov 16, 2026
81Police & Firemen's Retirement System of New Jersey23,0920 (0.00%)0.02%$0 MNov 9, 2026
82Gladstone Institutional Advisory LLC22,931+5,260 (+29.77%)0.02%$0 MNov 13, 2026
83Simplex Trading, LLC21,666-11,223 (-34.12%)0.02%$0 MNov 4, 2026
84FMR LLC21,524-38,500 (-64.14%)0.02%$0 MNov 10, 2026
85Ieq Capital, LLC20,649-93,599 (-81.93%)0.02%$0 MNov 10, 2026
86Dana Investment Advisors, Inc.20,4060 (0.00%)0.02%$0 MNov 13, 2026
87State Board Of Administration Of Florida Retirement System20,3450 (0.00%)0.02%$0 MNov 13, 2026
88Hamilton Point Investment Advisors, LLC20,3000 (0.00%)0.02%$0 MNov 3, 2026
89Brevan Howard Capital Management LP19,506New0.02%$0 MNov 16, 2026
90Voya Investment Management LLC19,4350 (0.00%)0.02%$0 MNov 10, 2026
91Royal Bank Of Canada19,418+15,797 (+436.26%)0.02%$0 MNov 16, 2026
92Advisory Alpha, LLC18,8390 (0.00%)0.02%$0 MNov 13, 2026
93New York State Common Retirement Fund18,2090 (0.00%)0.02%$0 MNov 17, 2026
94Integrated Wealth Concepts LLC17,202+300 (+1.77%)0.02%$0 MNov 17, 2026
95Mariner, LLC16,963-50,172 (-74.73%)0.02%$0 MNov 12, 2026
96China Universal Asset Management Co., Ltd.16,914+2,165 (+14.68%)0.02%$0 MOct 28, 2026
97Delta Asset Management Llc/tn16,0000 (0.00%)0.02%$0 MNov 10, 2026
98StoneX Group Inc.15,313-3,366 (-18.02%)0.02%$0 MNov 3, 2026
99Wealth Enhancement Advisory Services, LLC15,278-15,854 (-50.93%)0.02%$0 MOct 13, 2026
100Prudential Financial Inc15,1550 (0.00%)0.02%$0 MNov 16, 2026

All 165 institutional investors, with who bought and sold →

Mutual funds holding Anavex Life Sciences Corp.#

96 funds hold shares worth $43 M (about 17.1% of the company). Since their previous reports 50 added shares and 28 sold, selling $1 M net.
Mutual funds holding Anavex Life Sciences Corp.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.2.93 M$8 M3.2%<0.01%+7.1%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors2.42 M$6 M2.6%<0.01%+13%Jun 30, 2026
🇺🇸 Federated Hermes MDT Small Cap Core FundFederated Hermes MDT Series2.05 M$6 M2.2%0.25%+289%Jul 31, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.00 M$3 M1.1%<0.01%+15%Jul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.04 M$3 M1.1%<0.01%−0.4%Jun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors737,460$2 M0.80%0.01%newJun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors631,748$2 M0.68%0.02%−5.5%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC484,708$1 M0.52%<0.01%+7.1%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.450,282$1 M0.49%<0.01%+8.5%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.440,209$1 M0.47%<0.01%+5.3%May 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.266,123$1 M0.29%<0.01%+3.9%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors310,051$1 M0.33%0.05%+40%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.224,867$1 M0.24%<0.01%+17%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC175,983$1 M0.19%<0.01%+13%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC186,662$0 M0.20%<0.01%+32%Jun 30, 2026
🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors161,530$0 M0.17%0.01%−44%Jul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC140,123$0 M0.15%<0.01%+13%May 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors142,968$0 M0.15%<0.01%−80%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC122,064$0 M0.13%<0.01%+13%Jul 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors123,215$0 M0.13%<0.01%+2.5%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC123,000$0 M0.13%0.22%newJun 30, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.95,522$0 M0.10%0.18%+20%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC107,650$0 M0.12%0.01%newJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC100,888$0 M0.11%<0.01%+3.6%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.81,699$0 M0.09%0.01%+7.0%May 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.68,920$0 M0.07%<0.01%newMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC53,539$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC47,885$0 M0.05%0.09%—Apr 30, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.61,679$0 M0.07%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC61,470$0 M0.07%<0.01%+34%Jun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC56,923$0 M0.06%<0.01%+115%Jul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation58,700$0 M0.06%<0.01%no changeJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC53,570$0 M0.06%<0.01%+41%Jun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC49,361$0 M0.05%<0.01%+11%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.48,976$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC46,081$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.48,289$0 M0.05%<0.01%+11%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC44,051$0 M0.05%<0.01%+20%Jul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company38,163$0 M0.04%<0.01%+17%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.38,660$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC33,257$0 M0.04%<0.01%+1.8%Jul 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC31,271$0 M0.03%<0.01%+84%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.29,900$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC26,153$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Common Stock Index PortfolioEquitable Investment Management Group, LLC23,900$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP21,397$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS22,386$0 M0.02%<0.01%+31%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC22,357$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC20,931$0 M0.02%0.02%+33%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC20,441$0 M0.02%<0.01%+27%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC19,700$0 M0.02%<0.01%−3.0%Jun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors19,345$0 M0.02%<0.01%−0.8%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION15,300$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC16,591$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC14,445$0 M0.02%<0.01%−78%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.14,432$0 M0.02%<0.01%+19%Jun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.14,396$0 M0.02%<0.01%−4.5%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.14,061$0 M0.02%<0.01%+33%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC13,159$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC12,731$0 M0.01%<0.01%+31%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC12,007$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.10,379$0 M0.01%<0.01%+1.0%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC10,612$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC9,594$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS8,592$0 M<0.01%<0.01%+321%Jul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.8,422$0 M<0.01%<0.01%−4.8%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.6,160$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS6,627$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management6,984$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC6,739$0 M<0.01%<0.01%+23%Jun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC6,704$0 M<0.01%<0.01%+28%Jun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC6,263$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC6,397$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC6,340$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC5,000$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC4,864$0 M<0.01%<0.01%−66%Jul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP4,671$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC4,119$0 M<0.01%<0.01%+14%May 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC3,505$0 M<0.01%<0.01%−5.3%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC3,258$0 M<0.01%<0.01%−37%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC3,220$0 M<0.01%<0.01%−38%May 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC3,717$0 M<0.01%<0.01%−45%Jun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC3,585$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC3,186$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC2,431$0 M<0.01%<0.01%−79%Jun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC2,410$0 M<0.01%<0.01%+24%Jun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC2,026$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.2,253$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC1,840$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,635$0 M<0.01%<0.01%+12%Jun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC1,378$0 M<0.01%<0.01%−79%Jun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC1,221$0 M<0.01%<0.01%−79%Jul 31, 2026
🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC1,126$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.545$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC521$0 M<0.01%<0.01%+9.7%Jul 31, 2026
🇺🇸 E*TRADE No Fee Total Market Index FundMorgan Stanley Investment Management Inc.40$0 M<0.01%<0.01%—Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 96 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Anavex Life Sciences Corp.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
8
since
$23 K-$375 K$0Mar 2024: bought $0 (0 trades), sold $375 K (1 trades)Mar 24May 2024: bought $23 K (1 trades), sold $0 (0 trades)MayJun 2024: bought $10 K (1 trades), sold $0 (0 trades)Jun
Bought (open market)Sold (open market)Hover a month for the totals
Anavex Life Sciences Corp.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Christopher U. MisslingPresident and CEO, DirectorOption exercise+187,500$5.040$945 K1.66 MForm 4
filed Christopher U. MisslingPresident and CEO, DirectorShares withheld for tax-145,048$9.580$1.4 M1.51 MForm 4
filed Steffen ThomasDirectorOption exercise+50,000$1.760$88 K55,000Form 4
filed Steffen ThomasDirectorShares withheld for tax-11,349$7.750$88 K43,651Form 4
filed Christopher U. MisslingPresident and CEO, DirectorOption exercise+500,000$0.920$460 K1.75 MForm 4
filed Christopher U. MisslingPresident and CEO, DirectorShares withheld for tax-282,497$9.630$2.7 M1.47 MForm 4
filed Peter D.o. DonhauserDirectorBuy+2,835$3.640$10 K5,000Form 4
filed Steffen ThomasDirectorBuy+5,000$4.520$23 K5,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Anavex Life Sciences Corp.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
11.9 M
13.8% of shares · 10.11 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-11-14 14:39 UTC, code LUDP, resumed 14:44 UTC
  • 2025-11-14 14:33 UTC, code LUDP, resumed 14:38 UTC

Fails to deliver

  • : 5 shares at $1.33
  • : 778 shares at $1.36
  • : 21,210 shares at $1.31
  • : 2,971 shares at $1.49
  • : 1 shares at $1.48

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Anavex Life Sciences Corp. scorecard#

Passes 1 of the 11 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.3×Price to book 1.3× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-2.2%Free cash flow is -2.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.54 vs -0.52Diluted EPS -0.54 in fiscal 2025 against -0.52 the year before (report's currency).
    • ✗Net income higher than five years earlier-$46 M-$46 M in fiscal 2025 against -$26 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$46 MNet income -$46 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-43.1%-43.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 1
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year2.2%Diluted shares up 2.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Anavex Life Sciences Corp.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Anavex Life Sciences Corp.: statements by fiscal year
PeriodTrendFY 2025to Sep 30, 2025FY 2024to Sep 30, 2024FY 2023to Sep 30, 2023FY 2022to Sep 30, 2022FY 2021to Sep 30, 2021FY 2020to Sep 30, 2020FY 2019to Sep 30, 2019FY 2018to Sep 30, 2018FY 2017to Sep 30, 2017FY 2016to Sep 30, 2016
Income statement
Research and development38424438r33r252213117.3
Selling, general and administrative141112———————
General and administrative141112r13r9.0r5.96.86.05.08.3
Operating expenses515356r51r42r−31r29191616
Operating income−51−53−56r−51r−42r−31————
Net interest income4.77.36.50.9r0.0r0.20.20.30.10.0
Other non-operating income (expense)5.09.98.33.4r4.4r4.82.92.2r2.30.9
Income before tax−46−43−47−48r−38r−26−26−17r−13−15
Net income attributable to shareholders−46−43−48−48r−38r−26−26−17r−13−15
Earnings per share, basic-0.54-0.52-0.60-0.62-0.54-0.45-0.54-0.39-0.33-0.42
Earnings per share, diluted-0.54-0.52-0.60-0.62-0.54-0.45-0.54-0.39-0.33-0.42
Shares, weighted average (basic)8583807770————35
Shares, weighted average (diluted)85838077705849454135
Balance sheet
Cash and cash equivalents103132151149r152292223279.2
Other current assets0.40.90.70.4r0.4—0.51.3——
Current assets——————2526r289.4
Total assets104136154153r162352526r289.5
Accounts payable4.29.64.33.8r4.74.03.53.0r3.63.1
Current liabilities————117.35.03.93.63.2
Total liabilities8.9151310r117.35.0—3.63.2
Retained earnings−382−336−293−246r−198−160−133−107r−91−78
Shareholders' equity95120142142r151r27r2022r26r6.3
Total liabilities and equity104136154153r162352526r289.5
Shares outstanding87858278766253r464336
Cash-flow statement
Depreciation and amortization—————————0.0
Share-based compensation129.41618r8.2r4.96.45.54.15.1
Cash from operating activities−39−31−28−24r−30r−21−19−13−9.0−9.2
Shares issued—112821r153r29188.2273.2
Cash from financing activities9.4123021r153r28188.1273.1
Change in cash—————7.1−0.7———
Report10-K/A10-K/A10-K/A10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Anavex Life Sciences Corp. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.

Anavex Life Sciences Corp.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇦🇺 Australia1 subsidiary—
🇩🇪 Germany1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Anavex Life Sciences Corp.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Change in control 1 · Directors and officers 7 · Material agreement 1 · Agreement ended 1 · Shareholder vote 3 · Results announced 4

Anavex Life Sciences Corp.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Directors and officers8-K
Change in controlShareholder vote8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Agreement ended8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 3, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Anavex Life Sciences Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2014$10 MPrivate placement after listing$10 to $50 million11debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Anavex Life Sciences Corp.#

$240 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.

Lobbying, 2025
$240 K
#894 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$0
  • Health Issues4 reports

Lobbying firms hired in 2025

Forbes-Tate $240 K

Anavex Life Sciences Corp.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$0—1
2025$240 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Anavex Life Sciences”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Anavex Life Sciences Corp. compares in Biotechnology

  • Market cap$123 M · higher than 39% of 726
  • Price / book1.3× · lower than 71% of 534
  • FCF yield-2.2% · higher than 80% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Anavex Life Sciences Corp.🇺🇸$123 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending September-2025
Balance sheet:
As of September-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Anavex Life Sciences Corp.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Anavex Life Sciences Corp.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Anavex Life Sciences Corp.? Suggest a correction